• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment.

作者信息

Jian Yuan, Chang Long, Shi Ming-Xia, Sun Ying, Chu Xiao-Xia, Xue Hua, Huang Wen-Rong, Shen Xu-Liang, Ma Jie, Jia Guo-Rong, Feng Ya-Qing, Xi Zhen-Fang, Zhao Yan-Hong, Ma Yan-Ping, Xiao Jing, Ma Guang-Yu, Wang Qing-Ming, Bao Li, Dong Yu-Jun, Zhou He-Bing, Sun Chun-Yan, Su Guo-Hong, Yan Yan, Qimuge Sai-Yin, Su Li-Ping, Sun Jing-Nan, Tian Wei-Wei, Sun Xiu-Li, Jing Hong-Mei, Gao Da, Chen Wen-Ming, Li Jian, Gao Wen

机构信息

Department of Hematology, Myeloma Research Center of Beijing, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.

Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

出版信息

Blood Adv. 2023 Dec 26;7(24):7581-7584. doi: 10.1182/bloodadvances.2023011428.

DOI:10.1182/bloodadvances.2023011428
PMID:37922425
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10733092/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06d3/10733092/b4a12d391e1a/BLOODA_ADV-2023-011428-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06d3/10733092/b4a12d391e1a/BLOODA_ADV-2023-011428-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06d3/10733092/b4a12d391e1a/BLOODA_ADV-2023-011428-gr1.jpg

相似文献

1
Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment.泊马度胺、硼替佐米及地塞米松用于新诊断的肾功能不全多发性骨髓瘤患者
Blood Adv. 2023 Dec 26;7(24):7581-7584. doi: 10.1182/bloodadvances.2023011428.
2
Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.接受基于硼替佐米方案治疗的多发性骨髓瘤患者肾功能损害的可逆性：预测因素的识别
Clin Lymphoma Myeloma. 2009 Aug;9(4):302-6. doi: 10.3816/CLM.2009.n.059.
3
Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma.MM-003研究中肾功能损害的分析，这是一项关于泊马度胺+低剂量地塞米松对比高剂量地塞米松治疗难治性或复发难治性多发性骨髓瘤的III期研究。
Haematologica. 2016 Jul;101(7):872-8. doi: 10.3324/haematol.2015.137083. Epub 2016 Apr 14.
4
Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment.硼替佐米与地塞米松联合治疗新诊断的合并肾功能损害的多发性骨髓瘤患者。
Clin Lymphoma Myeloma. 2009 Oct;9(5):394-8. doi: 10.3816/CLM.2009.n.077.
5
Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients.皮下注射硼替佐米联合沙利度胺和地塞米松治疗新诊断的多发性骨髓瘤患者
Biomed Res Int. 2015;2015:927105. doi: 10.1155/2015/927105. Epub 2015 Sep 6.
6
Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency.来那度胺-地塞米松作为新诊断的伴有肾功能不全的多发性骨髓瘤患者自体干细胞移植前的诱导治疗。
Biol Blood Marrow Transplant. 2010 Aug;16(8):1115-21. doi: 10.1016/j.bbmt.2010.02.020. Epub 2010 Mar 1.
7
Dialysis Independence Following Combination Daratumumab, Thalidomide, Bortezomib, Cyclophosphamide, and Dexamethasone in Multiple Myeloma With Severe Renal Failure.达雷妥尤单抗、沙利度胺、硼替佐米、环磷酰胺和地塞米松联合治疗严重肾衰竭多发性骨髓瘤后的透析独立性
Clin Lymphoma Myeloma Leuk. 2020 Jul;20(7):e395-e398. doi: 10.1016/j.clml.2020.03.014. Epub 2020 Apr 7.
8
The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.新型药物在新诊断为多发性骨髓瘤的有症状患者肾功能损害可逆性中的作用。
Leukemia. 2013 Feb;27(2):423-9. doi: 10.1038/leu.2012.182. Epub 2012 Jul 5.
9
Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial.硼替佐米、苯达莫司汀和地塞米松对比沙利度胺、苯达莫司汀和地塞米松用于伴有肾衰竭的骨髓瘤患者（OPTIMAL）：一项随机、多中心II期试验
Blood Cancer J. 2022 Nov 29;12(11):162. doi: 10.1038/s41408-022-00758-7.
10
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.硼替佐米、沙利度胺、地塞米松和帕比司他用于复发多发性骨髓瘤患者（MUK-six）：一项多中心、开放标签的1/2期试验
Lancet Haematol. 2016 Dec;3(12):e572-e580. doi: 10.1016/S2352-3026(16)30165-X. Epub 2016 Nov 12.

引用本文的文献

1
Lowering the Selinexor Dose within the Pomalidomide and Dexamethasone Combination Regimen Elicits Fewer Side Effects While Comparable Efficacy Against Relapsed/Refractory Multiple Myeloma.在泊马度胺和地塞米松联合方案中降低塞利尼索剂量可减少副作用，同时对复发/难治性多发性骨髓瘤具有相当的疗效。
Onco Targets Ther. 2025 Jun 6;18:695-703. doi: 10.2147/OTT.S516486. eCollection 2025.
2
Appraisal of CRISPR Technology as an Innovative Screening to Therapeutic Toolkit for Genetic Disorders.CRISPR技术作为遗传疾病创新筛查和治疗工具的评估。
Mol Biotechnol. 2025 Feb 2. doi: 10.1007/s12033-025-01374-z.
3
Pre-exposure prophylaxis with tixagevimab/cilgavimab for coronavirus disease 2019 (COVID-19) during the Omicron BA.5 wave at a single institution in Japan.

本文引用的文献

1
Multiple myeloma with acute light chain cast nephropathy.多发性骨髓瘤伴急性轻链型 Cast 肾病。
Blood Cancer J. 2023 Mar 29;13(1):46. doi: 10.1038/s41408-023-00806-w.
2
Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE Phase II Study.泊马度胺、硼替佐米和地塞米松联合化疗治疗初诊多发性骨髓瘤的疗效和安全性：POMACE Ⅱ期研究。
Blood Cancer J. 2023 Mar 24;13(1):45. doi: 10.1038/s41408-023-00816-8.
3
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
在日本的一家机构中，针对奥密克戎 BA.5 波进行的 2019 年冠状病毒病（COVID-19）用替沙格韦单抗/西加韦单抗的预先暴露预防。
Int J Hematol. 2023 Dec;118(6):731-736. doi: 10.1007/s12185-023-03663-2. Epub 2023 Sep 25.
来那度胺预处理的多发性骨髓瘤患者首次复发时应用泊马度胺、硼替佐米和地塞米松：基于临床特征的 OPTIMISMM 亚分析。
Eur J Haematol. 2022 Jan;108(1):73-83. doi: 10.1111/ejh.13706. Epub 2021 Sep 22.
4
Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.多发性骨髓瘤：欧洲血液学协会-欧洲肿瘤内科学会诊断、治疗及随访临床实践指南
Hemasphere. 2021 Feb 3;5(2):e528. doi: 10.1097/HS9.0000000000000528. eCollection 2021 Feb.
5
Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy.比较双硼替佐米与三硼替佐米方案治疗多发性骨髓瘤伴因铸型肾病所致急性肾损伤患者的随机临床试验。
J Clin Oncol. 2020 Aug 10;38(23):2647-2657. doi: 10.1200/JCO.20.00298. Epub 2020 Jun 23.
6
An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment - validation of official dosing guidelines.一项关于来那度胺联合地塞米松治疗不同程度肾功能损害的初治多发性骨髓瘤（MM）患者的开放性、药代动力学研究 - 官方剂量指南的验证。
Leuk Lymphoma. 2020 Aug;61(8):1860-1868. doi: 10.1080/10428194.2020.1747064. Epub 2020 May 31.
7
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.来那度胺治疗后复发或难治性多发性骨髓瘤患者的泊马度胺、硼替佐米和地塞米松治疗（OPTIMISMM）：一项随机、开放标签、3 期试验。
Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13.
8
Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial.泊马度胺联合低剂量地塞米松治疗复发/难治性多发性骨髓瘤伴肾功能损害患者的疗效：一项 II 期试验结果。
J Clin Oncol. 2018 Jul 10;36(20):2035-2043. doi: 10.1200/JCO.2017.76.1742. Epub 2018 Feb 2.
9
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.国际骨髓瘤工作组多发性骨髓瘤反应和微小残留病评估的共识标准。
Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.
10
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment.国际骨髓瘤工作组关于骨髓瘤相关肾脏损害的诊断和管理建议。
J Clin Oncol. 2016 May 1;34(13):1544-57. doi: 10.1200/JCO.2015.65.0044. Epub 2016 Mar 14.